Summary
Hematopoietic stem/progenitor cell gene therapy (HSPC-GT) refers to the transfer of nucleic acids into HSPCs, to either add a new copy of a “healthy” gene or to correct a mutated gene. HSPC-GT is successfully used in clinic to treat patients with hematopoietic malignancies and several inherited diseases of the hematopoietic system. Yet, its current use is accompanied by acute conditioning-related toxicities, which impose a burden on patients and limit its application to the most severe conditions. HSPC-GT requires the following steps: HSPCs are mobilized and harvested from the patient, genetically corrected ex-vivo by gene transfer or gene editing and infused back to the patient, after administration of partial or fully myeloablative conditioning to make space in the bone marrow for the modified cells. Administered HSPCs home to the bone marrow, where they engraft and reconstitute a healthy immune system, theoretically throughout life. However, two major shortcomings undermine the full therapeutic potential of HSPC-GT: (i) a decrease in short- and/or long-term engraftment potential due to the ex vivo manipulation of HSPCs and (ii) a toxicity in the hematopoietic and non-hematopoietic organs related to the conditioning regimens, which are based on cytotoxic drugs. The project IMPROVING-GT proposes to develop innovative schemes to increase engraftment and dodge genotoxic conditioning, which are some of the most coveted but still unaccomplished goals of HSPC-GT. The candidate aims to (1) increase the fitness of genetically modified HSPCs by uncovering new players of engraftment and (2) bypass the toxic conditioning requirement by exploiting enhanced mobilization reagents. IMPROVING-GT will pave the way towards non or milder genotoxic regimens, which should greatly minimize undesirable toxicity of current treatments and ameliorate patients’ outcome. Moreover, it may help broadening applications of HSPC-GT to more diseases, including patients with lower disease burden.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/101031856 |
Start date: | 01-01-2022 |
End date: | 31-12-2023 |
Total budget - Public funding: | 183 473,28 Euro - 183 473,00 Euro |
Cordis data
Original description
Hematopoietic stem/progenitor cell gene therapy (HSPC-GT) refers to the transfer of nucleic acids into HSPCs, to either add a new copy of a “healthy” gene or to correct a mutated gene. HSPC-GT is successfully used in clinic to treat patients with hematopoietic malignancies and several inherited diseases of the hematopoietic system. Yet, its current use is accompanied by acute conditioning-related toxicities, which impose a burden on patients and limit its application to the most severe conditions. HSPC-GT requires the following steps: HSPCs are mobilized and harvested from the patient, genetically corrected ex-vivo by gene transfer or gene editing and infused back to the patient, after administration of partial or fully myeloablative conditioning to make space in the bone marrow for the modified cells. Administered HSPCs home to the bone marrow, where they engraft and reconstitute a healthy immune system, theoretically throughout life. However, two major shortcomings undermine the full therapeutic potential of HSPC-GT: (i) a decrease in short- and/or long-term engraftment potential due to the ex vivo manipulation of HSPCs and (ii) a toxicity in the hematopoietic and non-hematopoietic organs related to the conditioning regimens, which are based on cytotoxic drugs. The project IMPROVING-GT proposes to develop innovative schemes to increase engraftment and dodge genotoxic conditioning, which are some of the most coveted but still unaccomplished goals of HSPC-GT. The candidate aims to (1) increase the fitness of genetically modified HSPCs by uncovering new players of engraftment and (2) bypass the toxic conditioning requirement by exploiting enhanced mobilization reagents. IMPROVING-GT will pave the way towards non or milder genotoxic regimens, which should greatly minimize undesirable toxicity of current treatments and ameliorate patients’ outcome. Moreover, it may help broadening applications of HSPC-GT to more diseases, including patients with lower disease burden.Status
CLOSEDCall topic
MSCA-IF-2020Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping